Share this article
Pharma Giant Tests IBM Blockchain in Bid to Improve Clinical Trials
Pharma giant Boehringer Ingelheim is set to trial IBM blockchain in Canada to raise the quality of processes and records in clinical trials.
Updated Dec 12, 2022, 12:42 p.m. Published Feb 13, 2019, 9:00 a.m.
A Germany-based pharmaceutical multinational's Canadian arm is set to trial IBM blockchain in Canada in a bid to raise the quality of clinical trials.
Boehringer Ingelheim (Canada) announced Tuesday that it has partnered with IBM “to improve trust, transparency, patient safety and patient empowerment in clinical trials” using the tech giant's blockchain platform.
STORY CONTINUES BELOW
Don't miss another story.Subscribe to the Crypto Daybook Americas Newsletter today. See all newsletters
The firm said the trial aims to address quality issues with clinical trial processes and records, which are currently “often erroneous or incomplete” and could potentially put patient safety at risk.
The project will test how blockchain can help provide a decentralized framework that preserves the integrity of data, provides "provenance and transparency," and enables the automation of processes, ultimately boosting patient safety and reducing costs.
“The clinical trial ecosystem is highly complex as it involves different stakeholders, resulting in limited trust, transparency and process inefficiencies without true patient empowerment,” said Dr. Uli Brödl, vice president for medical and regulatory affairs at Boehringer Ingelheim (Canada).
IBM Canada’s general manager for services, Claude Guay, said:
“We’ve been using blockchain in other industries, and we are now investigating how we can use this technology to give Canadian patients the same level of security and trust when it comes to their personal health information.”
Other major pharmaceutical firms have also been exploring the potential benefits of integrating blockchain tech. In January 2018, Pfizer, Amgen and Sanofi were eyeing blockchain as a way of streamlining the process of developing and testing new drugs.
Last June, Merck was seeking a patent for a way to use blockchain in order to track goods as they move through the supply chain and tackle the issue of counterfeit meds. Indian government think tank NITI Aayog was also working on a blockchain solution aimed to combat the country’s roaring counterfeit drugs trade last April.
Test tubes in medical lab image via Shutterstock
More For You
What to know:
- As of October 2025, GoPlus has generated $4.7M in total revenue across its product lines. The GoPlus App is the primary revenue driver, contributing $2.5M (approx. 53%), followed by the SafeToken Protocol at $1.7M.
- GoPlus Intelligence's Token Security API averaged 717 million monthly calls year-to-date in 2025 , with a peak of nearly 1 billion calls in February 2025. Total blockchain-level requests, including transaction simulations, averaged an additional 350 million per month.
- Since its January 2025 launch , the $GPS token has registered over $5B in total spot volume and $10B in derivatives volume in 2025. Monthly spot volume peaked in March 2025 at over $1.1B , while derivatives volume peaked the same month at over $4B.
More For You
Coinbase Sees Crypto Recovery Ahead as Liquidity Improves and Fed Rate Cut Odds Climb
The crypto exchange also took note of a so-called AI bubble that continues to go strong and a weaker U.S. dollar.
What to know:
- Coinbase Institutional is seeing a potential December recovery in crypto, citing improving liquidity and a shift in macroeconomic conditions that could favor risk assets like bitcoin.
- The firm's optimism is driven by rising odds of Federal Reserve rate cuts, with markets pricing in a 93% chance easing next week, and improving liquidity conditions.
- Several recent institutional developments, including Vanguard's crypto ETF policy reversal and Bank of America's greenlighting of crypto allocations, have contributed to bitcoin's rebound from recent lows.
Top Stories
